Intravenous tPA (Tissue-Type Plasminogen Activator) in Patients with Acute Ischemic Stroke Taking Non-Vitamin K Antagonist Oral Anticoagulants Preceding Stroke
Stroke 49:2237-2240, Jin, C.,et al, 2018
Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients with Atrial Cardiopathy, The ARCADIA Randomized Clinical Trial
JAMA 331:573-581, Kamel,H.,et al, 2024
Economic Evaluation of Andexanet Versus Prothrombin Complex Concentrate for Reversal of Factor Xa-Associated Intracranial Hemorrhage
Stroke 52:1390-1397, Micieli, A.,et al, 2021
Clinical Outcomes in Atrial Fibrillation Patients with a History of Cancer Treated with Non-Vitamin K Antagonist Oral Anticoagulants
Stroke 52:3132-3141, Chan, Y.H.,et al, 2021
Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer
NEJM 382:1599-1607,1650, Agnelli, G.,et al, 2020
Andexxa-An Antidote for Apixaban and Rivaroxaban
JAMA 320:399-400, , 2018
Coagulation Test Interpretation in a Patient Taking Direct Oral Anticoagulant Therapy
JAMA 320:1485-1486, Sholzberg, M. & Xu, Y., 2018
Oral Anticoagulants for Prevention of Stroke in Atrial Fibrillation: Systematic Review, Network Meta-Analysis, and Cost Effectiveness Analysis
BMJ 359:J5058, Lopez-Lopez, J.A.,et al, 2017
Which Oral Anticoagulation for Atrial Fibrillation?
JAMA 315:2117-2118, The Medical Letter, 2016
Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity
NEJM 373:2413-2424,2471, Siegal, D.M.,et al, 2015
Rethinking Warfarin for Atrial Fibrillation
JAMA 311:1246, Zuccott, G & Pflomm, J.M., 2014
Oral Anticoagulants and the Risk of Intracranial Hemorrhage
JAMA 312:2562-2563, Vespa, P.M., 2014
Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation
Stroke 44:1676-1681, Harringotn, A.,et al, 2013
Critique of Apixaban Versus Warfarin in Patients with Atrial Fibrillation
Stroke 43:922-923, Nedeltchev,K, 2012
Progress for Stroke Prevention with Atrial Fibrillation
Stroke 43:1179-1185, Katsnelson,M.,et al, 2012
Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomized controlled trial
Lancet 380:1749-1758, Lopes, R.,et al, 2012
Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibrillation
Stroke 43:3442-3453, Furie, K.,et al, 2012
Bleeding During Treatment with Aspirin Versus Apixaban in Patients with Atrial Fibrillation Unsuitable for Warfarin
Stroke 43:3291-3297, Flaker, G.,et al, 2012
Nonvitamin K-Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack
Stroke 43:3298-3304, Ntaios, G.,et al, 2012
Apixaban in Patients With Atrial Fibrillation
NEJM 364:806-817, Connolly,S.J.,et al, 2011
Apixaban in Atrial Fibrillation From Bleeding Cows to 21st Century Medicinal Chemistry
Stroke 42:2376-2378, Cucchiara, B.L.,et al, 2011
Apixaban versus Warfarin in Patients with Atrial Fibrillation
NEJM 365:981-992,1052, Granger, C.B.,et al, 2011